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BACKGROUND: Prevalence of comorbidity at breast cancer diagnosis increases with age and is likely to influence the likelihood of
receiving treatment according to guidelines. The aim of this study was to examine the effect of breast cancer treatment on mortality,
taking age at diagnosis and comorbidity into account.
METHODS: Four nationwide population registries in Denmark: the Danish Civil Registration System, the Danish Breast Cancer
Cooperative Group, the Danish National Patient Register, and the Danish Register of Causes of Death provided information on
62 591 women diagnosed with early-stage breast cancer, 1990–2008, of whom data on treatment were available for 39 943.
Comorbidity was measured using the Charlson Comorbidity Index. Adjuvant treatment were categorised as none, chemotherapy,
endocrine therapy, and unknown. Multivariable Cox modelling assessed the effect of comorbidity on breast cancer-specific mortality
and other cause mortality according to treatment, adjusting for age at diagnosis and other clinical prognostic factors.
RESULTS: The impact of comorbidity on mortality was most pronounced in patients aged 50–79 years. Patients receiving
chemotherapy with mild to moderate comorbidity had HR 0.99 (95% confidence interval (CI); 0.82–1.19) and 1.06 (95% CI; 0.77–
1.46) for breast cancer-specific mortality, respectively, compared with patients without comorbidity.
CONCLUSION: Comorbidity at breast cancer diagnosis is an independent adverse prognostic factor for death after breast cancer. We
identified a subgroup of patients with mild to moderate comorbidity receiving chemotherapy who had similar breast cancer mortality
as patients with no comorbidity.
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Evidence on the effect of treatment for early-stage breast cancer
derives from randomised clinical trials (RCT) with strict inclusion
criteria, such as age, stage of disease, and, in particular, absence of
other diseases, which may interfere with the treatment or increase
the risk of death (EBCTCG, 2005a, b). These inclusion criteria
usually ensure that the patients are relatively young and healthy,
that is, free from comorbidity, in order to make the most
favourable comparison of the ‘experimental’ vs the ‘standard’
treatment (Lewis et al, 2003). Treatment guidelines tend to be
based on the results of RCTs. Several studies report that patients
aged 65 years or more at diagnosis do not receive treatment
according to guidelines just because of their age whereas treatment
choice was not influenced by comorbidity (Houterman et al, 2004;
Land et al, 2012b). Others have found that patients with
comorbidity received less treatment than recommended by guide-
lines, though the rate of complications to treatment should be
similar among those with and without comorbidity (Yancik et al,
2001; Louwman et al, 2005). In Denmark, comorbidity was present
in 26% of breast cancer patients diagnosed 2006–2008 and
presence of comorbidity increased the risk of dying from breast
cancer as well as of other causes (Land et al, 2012a). The aim of
this study was to examine the association of early-stage breast
cancer and mortality, taking age at diagnosis and comorbidity into
account.
MATERIALS AND METHODS
Data sources and study factors
Data for the present study were obtained by linking information
from four nationwide population registries in Denmark: the
Danish Civil Registration System (CRS), the Danish Breast Cancer
Cooperative Group (DBCG), the Danish National Patient Register,
and the Danish Register of Causes of Death described briefly
below.
Civil Registration System was established in 1968 and registers
all persons alive and living in Denmark with updated records of
vital status and dates of migration. All persons registered in CRS
are issued with a unique personal identification number, the CPR
number. This CPR number was the key identifier for the record
linkages (Pedersen, 2011). Danish Breast Cancer Cooperative
Group has performed clinical trials and issued national guidelines
for treatment since 1977. Data have been collected on diagnosis,
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histopathology, and surgery for all newly diagnosed early-stage
breast cancer patients in Denmark (Møller et al, 2008). For patients
enrolled into a clinical trial or who were treated according to the
guidelines (denoted ‘treatment programme’), information on
adjuvant therapy (radiotherapy and medical) is collected. Exclu-
sion criteria were recorded for patients not enrolled into a clinical
trial or treatment programme. The National Patient Registry has
registered information on all somatic hospital admissions since
1977, and since 1995 data on outpatient and emergency visits, with
up to 20 diagnoses per hospitalisation/contact (Lynge et al, 2011).
Comorbidity was measured using the Charlson Comorbidity Index
(CCI) (Charlson et al, 1987) developed to predict 1-year mortality
in medical inpatients, and subsequently validated among breast
cancer patients, and against other comorbidity indices
(Extermann, 2000b; Klabunde et al, 2007). The CCI provides an
overall score for comorbidity based on 19 selected conditions and
was categorised as 0, 1, 2, and 3þ . Diagnoses other than breast
cancer were collected from 10 years before the breast cancer
diagnosis and up to the breast cancer diagnosis. Diagnoses of other
malignancies in the 2-month period preceding the breast cancer
diagnoses were excluded to reduce possible overestimation of
malignancies, in the period of diagnostic work-up. The Danish
Register of Causes of Death was established in 1875 by the National
Board of Health. Since 1970s the register has been fully
computerised and includes data of all deaths among Danish
residents dying in Denmark (Helweg-Larsen, 2011).
Study population
The nationwide study population consisted of 62 591 women
diagnosed with early-stage breast cancer from 1990 through 2008.
Complete information on allocated and received treatment was
available for 39 943 (64%) of the cohort, while 17 338 patients were
not enrolled into a treatment programme. This group included
patients aged 75 or older at diagnosis, who up to 2002 were not
included into the national treatment guidelines, and patients who
were ineligible for a treatment programme because they were
inoperable, had contraindications for the planned treatment,
bilateral breast cancer, prior malignant disease, bone-marrow
transplant, metastases at diagnosis, death within 4 weeks of
diagnosis, patients’ wish, or other causes. For 5310 patients,
information was available to allocate the patients into a treatment
programme, but no information was recorded on whether the
treatment was actually received (Figure 1). Table 1 shows details
on tumour characteristics.
Statistical analyses
Associations between CCI score and age at breast cancer diagnosis,
and between CCI score and breast cancer treatment were analysed
by w2 tests. Overall survival (OS) was calculated using the Kaplan–
Meier method, estimating the time from date of surgery until
death, irrespective of cause of death, or end of follow-up (31
December 2008). All patients had a surgical intervention: biopsy,
lumpectomy, or mastectomy. Cumulative mortality in the presence
of competing risks was estimated for deaths from breast cancer,
and deaths from other causes, according to CCI score for age at
breast cancer diagnosis and treatment, respectively (Grey, 1988;
Gooley et al, 1999). The Cox proportional hazards regression
model was used (Cox, 1972), to assess the adjusted influence of
CCI according to age at breast cancer diagnosis and treatment on
breast cancer-specific mortality and other cause mortality, with
CCI score 0 as reference, and time since breast cancer diagnosis as
underlying time scale. Adjustments were made for factors
associated with prognosis, such as age at breast cancer diagnosis,
menopausal status (pre- or postmenopausal according to DBCG
criteria (Møller et al, 2008)), tumour size, nodal status, deep fascia
invasion, vascular invasion, histological type and grade, hormone
receptor status, calendar year of diagnosis, and type of surgery and
adjuvant treatment. The latter was categorised as: no adjuvant
medical treatment ( ), chemotherapy (CT) alone or followed by
endocrine therapy, and endocrine therapy (E) without chemother-
apy. The assumptions of proportional hazards were assessed by
plot of Schoenfeld residuals against time and by formal tests
(Schoenfeld, 1982). The hazard rates of histological type and grade
as well as hormone receptor status were not proportional, and
stratified Cox regression was used (Grambsch and Therneau, 1994;
Therneau and Grambsch, 2000). To assess possible effect
modification, interactions between CCI score and age at breast
cancer diagnosis, and between CCI score and received treatment,
were investigated in the multivariable Cox model using the Wald
test. The division of age at breast cancer diagnosis into three
categories, less than 50 years, 50–79 years, and 80 years or more,
derived from multivariable analyses of interactions, of 10-year age
groups where those with similar effects of CCI were grouped
together. Tests of statistical hypotheses were done on the two-sided
5% level of significance. Statistical analyses were performed with
the SAS v9.1 statistical software (SAS Institute, Inc., Cary, NC,
USA).
RESULTS
Age at breast cancer diagnosis and comorbidity
The proportion of breast cancer patients with one or more
comorbid conditions at diagnosis increased significantly
(Po0.0001) with increasing age at breast cancer diagnosis from
7% among the 12 924 women agedo50 years to 21% in the 43 225
aged 50–79 years, and reaching 40% among 6442 women 80 years
or older (Table 1).
Among patients aged o50 years at breast cancer diagnosis,
breast cancer-specific mortality was fairly similar for CCI scores
0–2, but increased for those with CCI 3þ (Figure 2A). In this age
group, breast cancer was the dominant cause of death with few
deaths from other causes (Figure 2B). In patients aged 50–79 years
at breast cancer diagnosis, mortality increased with CCI score
(Figure 2C and D) whereas no such increase was observed in
All women diagnosed with breast cancer
1990–2008 in Denmark. N = 62 591
Enrolled in treatment
programme. N =45 253 (72)
Patients with known
adjuvant treatment
N = 39 943 (64)
Not enrolled in a treatment
programme. N = 17 338 (28)
Patients enrolled in a treatment
programme without information on
received treatment. N = 5310 (8)
Figure 1 Diagram showing the study cohort according to received
treatment. N, (%).
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patients aged 80þ for breast cancer mortality (Figure 2E). While
deaths from breast cancer contributed more than deaths from
other causes in all age groups, other cause mortality was much
higher in patients aged 80 or more years (Figure 2F). A
multivariable analysis showed a statistically significant
(Po0.0001) interaction between age at breast cancer diagnosis
and comorbidity on all cause mortality when adjusting for the
effects of known prognostic factors (data not shown).
Treatment and comorbidity
Figure 3 illustrates OS with 10-year estimates specified among
45 253 breast cancer patients enrolled into a treatment programme
and 17 338 not enrolled. Survival decreased statistically significant
with increasing CCI score; except for non-enrolled patients with
CCI score 2 who had better survival compared with CCI score 1.
Patients not enrolled in a treatment programme had an OS about
half that of patients enrolled. After 15 years,o25% of the patients
treated outside treatment programme were still alive.
Of the 39 943 patients with known adjuvant treatment, 14 795
(37%) belonged to the low-risk group who received no adjuvant
treatment, 11 459 (29%) patients received chemotherapy with 4179
of these receiving subsequent endocrine treatment, while 13 689
patients received endocrine treatment alone (Table 1). There was a
statistically significant interaction between CCI score and treat-
ment on breast cancer-specific mortality, non-breast cancer
mortality, and all cause mortality with Po0.0001 across all strata
for each outcome. Figure 4 shows breast cancer-specific mortality
in relation to comorbidity stratified by treatment. Among patients
who did not receive adjuvant medical treatment (low-risk
patients), those with any comorbidity (CCI 1þ ) had a higher
mortality than those without comorbidity (CCI 0) but mortality
did not vary much for CCI scores of 1–3þ (Figure 4A). Patients
receiving chemotherapy had similar mortality rates for CCI scores
of 0–2 while those with CCI of 3þ had a considerably higher
mortality (Figure 4B). In the endocrine treatment group, mortality
was similar for patients with CCI score 1and 2 (Figure 4C).
These univariable mortality estimates (Figure 4) were adjusted
by multivariable analysis for the effect of other factors known to be
associated with breast cancer prognosis and the results are
presented in Figure 5. This confirmed that compared with patients
with CCI¼ 0, any comorbidity (CCI scores 1–3) was associated
with statistically significant increased breast cancer mortality with
HRs of 1.56–1.86 among patients with no adjuvant medical
treatment. In patients receiving chemotherapy, HRs of 0.99 (95%
confidence interval (CI); 0.82–1.19) and HR 1.06 (95% CI; 0.77–
1.46) for CCIs 1 and 2 were observed compared with women with
CCI score 0 while HR for CCI score 3þ was 1.50 (95% CI; 0.98–2.32).
All patients in the endocrine therapy group with comorbidity (CCI
1–3þ ) had increased HRs ranging from 1.23 to 1.60 (Figure 5A).
Breast cancer was the dominant cause of death for patients in all
the treatment categories, and as expected, comorbidity highly
affected other cause mortality irrespective of treatment group
(Figure 5B).
DISCUSSION
This study confirms that comorbidity at breast cancer diagnosis is
an independent adverse prognostic factor for death after breast
cancer and that the effect of comorbidity varied by age at diagnosis
and by treatment. The relationship between age at breast cancer
diagnosis, comorbidity, and mortality is complex as demonstrated
by a statistically significant interaction. In patients aged o50
years, comorbidity is relatively rare and the predominant cause of
death is breast cancer, probably owing to a more unfavourable
prognostic profile. Among patients aged 50–79 years, there was a
pronounced effect of comorbidity on mortality that increased with
Table 1 Distribution of age at breast cancer diagnosis, adjuvant medical
treatment, and tumour characteristics by comorbidity score
Charlson comorbidity score (%)
0 1 2 3þ Total
N, (row %)
Age
o50 11 988 (93) 570 (4) 260 (2) 106 (1) 12 924
50–79 34 005 (79) 4939 (11) 2735 (6) 1546 (4) 43 225
80þ 3835 (60) 1325 (21) 745 (12) 537 (8) 6442
Adjuvant treatment
—a 12 481 (84) 1423 (10) 611 (4) 280 (2) 14 795
CTb 10 440 (91) 701 (6) 244 (2) 74 (1) 11 459
E 11 036 (81) 1631 (12) 688 (5) 334 (2) 13 689
Treatment unknown 15 871 (70) 3079 (14) 2197 (10) 1501 (7) 22 689
Total 49 828 (79) 6834 (11) 3740 (7) 2189 (4) 62 591
Tumour characteristics
N, (col %)c 47 911 6343 3412 1868 59 534
Tumour size (mm)
o10 7041 (15) 862 (13) 471 (14) 254 (14) 8628
11–20 18 927 (39) 2531 (40) 1348 (40) 677 (36) 23 483
21–50 18 498 (39) 2531 (40) 1377 (40) 789 (42) 23 195
51þ 2351 (5) 301 (5) 134 (4) 97 (5) 2883
Unknown 1094 (2) 118 (2) 82 (2) 51 (3) 1345
Oestrogen receptor status
Negative 9983 (21) 1146 (18) 636 (19) 387 (21) 12 152
Positive 34 566 (72) 4842 (76) 2543 (74) 1382 (74) 43 333
Unknown 3362 (7) 355 (6) 233 (7) 99 (5) 4049
Removed lymph nodes
SN 5675 (12) 963 (15) 482 (14) 244 (13) 7364
0 1829 (4) 542 (8) 318 (9) 259 (14) 2948
1–3 1172 (2) 232 (4) 118 (4) 71 (3) 1593
4–9 8386 (17) 915 (14) 474 (14) 258 (14) 10 033
10þ 30 634 (64) 3653 (58) 1993 (58) 1026 (55) 37 306
215 (1) 38 (1) 27 (1) 10 (1) 290
Tumour-positive lymph nodes
0 23 824 (50) 3024 (48) 1659 (49) 780 (42) 29 287
1–3 13 516 (28) 1684 (26) 857 (25) 455 (24) 16 512
4þ 8516 (18) 1059 (17) 551 (16) 364 (19) 10 490
Unknown 2055 (4) 576 (9) 345 (10) 269 (14) 3245
Histological type and grade
Ductal, gr. I 11 811 (25) 1635 (26) 879 (26) 444 (24) 14 769
Ductal, gr. II 16 489 (35) 2160 (34) 1177 (34) 620 (33) 20 446
Ductal, gr.III 9038 (19) 1068 (17) 587 (17) 359 (19) 11 052
Ductal, gr.? 1087 (2) 127 (2) 52 (2) 41 (2) 1307
Lobular 5438 (11) 768 (12) 388 (11) 225 (12) 6819
Others 3492 (7) 510 (8) 279 (8) 144 (8) 4425
Unknown 556 (1) 75 (1) 50 (2) 35 (2) 716
Fascial invasion
Yes 44 642 (93) 5946 (94) 3189 (93) 1764 (94) 55 541
No 1888 (4) 243 (4) 119 (4) 56 (3) 2306
Unknown 1381 (3) 154 (2) 104 (3) 48 (3) 1687
Abbreviations: CT¼ chemotherapy; E¼ endocrine therapy; gr.¼ grade; SN¼ sentinel
node diagnostics. aNo adjuvant medical treatment. bCT and E distributed as follows:
CMF (cyclophosphamide, methotrexate and fluorouracil) (4122), FEC (fluorouracil,
epirubicin and cyclophosphamide) (5459), and EC and docetaxel (1878). Trastuzumab
was given to 587 patients following chemotherapy with FEC or EC and docetaxel.
E was almost evenly distributed between tamoxifen alone and tamoxifen followed
by aromatase inhibitors (AI), and B10% AI alone. cTumour characteristics were
available on 59 534 patients, as 3057 patients were treated with biopsy only.
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Breast cancer deaths, < 50 years
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Figure 2 Cumulative mortality (%) from breast cancer and other causes, according to age at diagnosis and comorbidity score. (A, B) Less than 50 years,
(C, D) 50–79 years, and (E, F) 80þ years. The cumulative mortality at 10 years is listed for each category.
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increasing CCI score for deaths from breast cancer as well as from
other causes. This agrees well with the results from Colzani et al
(2011), who demonstrated that the proportion of breast cancer
deaths was higher among women younger than 54 years at
diagnosis compared with women aged 65–74 years, whereas the
proportion of deaths of other causes increased with age at breast
cancer diagnosis. In patients aged 80 or more, about 50% died of
breast cancer within 10 years irrespective of comorbidity while the
risk of dying from other causes increased with increasing CCI
score. It is often difficult to define a single, disease-specific,
underlying cause of death in the very old. Discrepancy in causes of
death classification between the National Mortality Register and a
study committee showed that the proportion of disagreement
increased in patients dying at age 85 or older, compared with those
dying at age 70 years and younger. Still a high agreement was
observed for neoplasms (Alpe´rovitch et al, 2009).
Age at breast cancer diagnosis may affect treatment decisions,
oncologists being more likely to prescribe chemotherapy for a
high-risk patient aged 68 years than to an otherwise identical
patient aged 73 years (Alistair, 2010). Several studies have reported
that elderly cancer patients were undertreated according to
national guidelines (Maskarinec et al, 2003; Janssen-Heijnen
et al, 2005; Bouchardy et al, 2007; Schonberg et al, 2010; Van
Leeuwen et al, 2011). This has also been the case in Denmark
where patients aged 75 years or older were not included in the
DBCG treatment guidelines up to 2002. Thus, no breast cancer
treatment or less than guideline treatment may be a likely
explanation for the poorer breast cancer outcome in the oldest
age groups.
Previous studies have demonstrated that comorbidity at breast
cancer diagnosis increases the risk of dying from breast cancer
(Cronin-Fenton et al, 2007; Carlsen et al, 2008; Du et al, 2008; Land
et al, 2012a). As with age at breast cancer diagnosis, comorbidity
may affect the choice of adjuvant treatment. Patients with severe
comorbidity tend to be excluded from RCTs, and the present study
demonstrated that patients not enrolled into a treatment
programme had twice the breast cancer mortality of those enrolled.
Other studies have shown that women who received guideline
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Figure 3 Kaplan–Meier curves showing OS according to comorbidity score for patients (A) enrolled in treatment protocol and (B) non-enrolled in
treatment protocol. The OS rate at 10 years is listed for each category.
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treatment for early-stage breast cancer were statistically significant
less likely to die within 5 years than women who did not
(Schonberg et al, 2011), and that breast cancer patients with
comorbidity had less extensive treatment and a poorer prognosis
than patients without comorbidity (Louwman et al, 2005). With
the increasing longevity of the female population, oncologists have
to face an increasing number of breast cancer patients with
comorbidity at diagnosis. It was therefore reassuring to find that
among patients for whom chemotherapy was given, the risk of
dying from breast cancer was similar for those with mild to
moderate comorbidity (CCI scores of 1 and 2) as for those without
comorbidity (CCI¼ 0). We are not aware of other studies reporting
similar results and consider this finding new. It should be
cautioned, though, that this analysis was based on 945 patients
with CCI of 1 or 2. This group may have included patients whose
comorbidity did not involve organ failure or posed contra-
indication for chemotherapy.
This study has several strengths. It included a large sample size
of 62 591 women diagnosed with breast cancer in Denmark, during
an 18-year time period from 1990–2008, with complete follow-up
for vital status and causes of death. Information on received breast
cancer treatment was available for 39 943 women included in the
analysis of treatment and we were able to examine mortality
among those for whom treatment was unknown. The information
available in the registers is exhaustive, with detailed information
on disease characteristic and regarding comorbidity with complete
registration of hospitalisations and outpatient visits. We used the
CCI, which has been validated in a cohort of breast cancer patients.
It is widely used and makes our results comparable with those of
others. When mortality is the outcome of interest, the CCI has
proven to be a valid and highly appropriate method for measuring
comorbidity (Extermann, 2000a; de Groot et al, 2003).
This study has some limitations too. There was no information
on received breast cancer treatment for 36% of the entire cohort
and according to CCI, information was unknown for 45% of
patients with CCI¼ 1, 58% with CCI¼ 2, and 68% with CCI¼ 3.
This group is likely to differ from those with similar comorbidity
but receiving treatment, leading to potential selection bias. The
CCI does not distinguish between severities of the specific
conditions, which means that patients with, that is, mild or severe,
chronic obstructive pulmonary disease are weighted the same
according to the index. Furthermore, the Danish National Patient
Registry does not include information on comorbidity that did not
require a hospital visit. However, the diseases in the CCI are
generally of such serious nature that at some point in the 10-year
period preceding breast cancer diagnosis the patient would need a
hospital or outpatient contact. Since 1995, the Danish National
Patient Registry included emergency and outpatient visits, which
could partly explain the increased proportion of comorbidity with
calendar time (Land et al, 2012a), though the patients added might
be patients with less severe comorbid conditions. Also there are
more treatment options for comorbid conditions, which earlier
might have been left untreated. Causes of death were ascertained
from the Danish Register of Causes of Death and may cause
potential misclassification. The validity of the registration of
causes of death is threatened by a low and declining autopsy rate.
In Denmark at present, the autopsy rate is below 10%, and
discontinuity may exist in the reported mortality by uncertain
conditions. Furthermore, the quality of the data relies mainly upon
the correctness of the physicians’ notification (Helweg-Larsen,
2011). Finally, we were not able to adjust for potential
confounders, such as overweight, alcohol consumption, and
oestrogen supplement, which were not recorded in the registries.
In conclusion, comorbidity at breast cancer diagnosis is an
independent adverse prognostic factor for death after breast
cancer. The effect of comorbidity on mortality varies with age at
diagnosis and with treatment. We identified a subgroup of patients
with mild to moderate comorbidity receiving chemotherapy who
had similar breast cancer mortality as patients with no
comorbidity.
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